Full history for every metric is available with a Kvantra account
scPharmaceuticals Inc. (SCPH)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 14 | 36 | 50 |
| Operating profit | $m | -65 | -67 | |||||
| Net profit | $m | -34 | -32 | -28 | -37 | -55 | -85 | -92 |
| EPS reported | $ | -1.91 | -1.88 | |||||
| Operating cashflow per share | $ | -1.58 | -0.62 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -1.58 | -0.62 | |||||
| Free cash flow | $m | -71 | -66 | |||||
| Net debt | $m | -24 | 11 | |||||
| Book value equity | $m | 13 | -21 | |||||
| Book value per share | $ | 0.30 | -0.40 | |||||
| Number of shares | m | 44.52 | 53.72 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 11.83 | -14.18 | |||||
| P/S LTM | x | 4.34 | 6.05 | |||||
| P/FCF LTM | x | -2.23 | -4.59 | |||||
| EV/EBITDA LTM | x | -1.74 | -3.67 | |||||
| EV/Sales LTM | x | 3.71 | 6.28 | |||||
| Earnings Yield LTM | % | -54.03% | -12.40% | |||||
| FCF Yield | % | -44.77% | -21.80% | |||||
| Quality | ||||||||
| ROE | % | -639.25% | 285.64% | |||||
| ROIC | % | -69.74% | -53.34% | |||||
| Operating margin | % | -178.29% | -115.32% | |||||
| Gross margin | % | 68.73% | 69.48% | |||||
| FCF/Sales | % | -194.21% | -119.63% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +167.28% | +107.79% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -1.34 | -1.23 | |||||
| Net Debt/EBITDA | x | 0.30 | -0.36 | |||||
| EBIT/Net interest | x | -8.56 | -11.50 | |||||
| Net debt/market cap | % | -15.42% | 3.76% | |||||
| Net debt/Equity | x | -1.82 | -0.53 | |||||
| Gross debt/equity | x | 3.96 | -2.51 | |||||
Company overview
scPharmaceuticals Inc. is a pharmaceutical firm dedicated to developing and commercializing a variety of medicinal products. Its primary investigational therapy, FUROSCIX, is a specialized formulation of furosemide delivered through an on-body infusor, intended for managing congestion in heart failure patients. The company's pipeline also encompasses scCeftriaxone, an antibiotic aimed at treating infections caused by both gram-positive and gram-negative bacteria, as well as the scCarbapenem program, another antibiotic designed for gram-negative bacterial infections. Additionally, scPharmaceuticals has entered into a collaboration agreement with West Pharmaceutical Services, Inc. for the advancement of a single-use SmartDose device. Founded in 2013, the company's main operations are based in Burlington, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
scPharmaceuticals Inc. (SCPH)
scPharmaceuticals Inc. is a pharmaceutical firm dedicated to developing and commercializing a variety of medicinal products. Its primary investigational therapy, FUROSCIX, is a specialized formulation of furosemide delivered through an on-body infusor, intended for managing congestion in heart failure patients. The company's pipeline also encompasses scCeftriaxone, an antibiotic aimed at treating infections caused by both gram-positive and gram-negative bacteria, as well as the scCarbapenem program, another antibiotic designed for gram-negative bacterial infections. Additionally, scPharmaceuticals has entered into a collaboration agreement with West Pharmaceutical Services, Inc. for the advancement of a single-use SmartDose device. Founded in 2013, the company's main operations are based in Burlington, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free